Laspas Panagiotis, Hartmann Alica, Scholz Ida, Hoffmann Esther Maria, Khawaja Anthony P, Lackner Karl Johannes, Münzel Thomas, Kerahrodi Jasmin Ghaemi, Schmidtmann Irene, Tüscher Oliver, Schattenberg Jörn Markus, Pfeiffer Norbert, Konstantinides Stavros, Wild Philipp Sebastian, Schuster Alexander Karl-Georg
Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust & UCL Institute of Ophthalmology, London, United Kingdom.
Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):4. doi: 10.1167/iovs.65.14.4.
The purpose of this study was to investigate the relationship between the change in systemic medication and intraocular pressure (IOP) on a population-based level.
The Gutenberg Health Study is a population-based prospective observational cohort study in Germany. As part of the baseline examination (2007-2012) and 5-year follow-up examination (2012-2017), IOP was measured by non-contact tonometry. Systemic medication was recorded at both time points. Multivariable regression analyses were carried out to analyze associations. Moreover, we calculated the dose-response relationship for the dosage change of selective beta-blockers with IOP change over 5 years.
The analysis population included 19,161 eyes of 9633 participants. IOP change was lower in participants with new intake of selective beta-blockers (-0.31 mm Hg, P < 0.001) and increased in those with discontinuation of selective beta-blocker intake (+0.28 mm Hg, P = 0.02). Associations between IOP change and statins and calcium channel blockers (CCBs) could be attributed to co-medications. There was a dose-response relationship for change in selective beta-blocker intake and change in IOP (-0.16 mm Hg/100 mg, P = 0.02).
Use of systemic selective beta-blockers is associated with an IOP change on a population level, whereas the association with other systemic medications on IOP change could be explained by co-medication use or change in blood pressure. Patients undergoing IOP monitoring and management should routinely be asked about changes in systemic medications.
本研究旨在在人群层面调查全身用药变化与眼压(IOP)之间的关系。
古登堡健康研究是德国一项基于人群的前瞻性观察性队列研究。作为基线检查(2007 - 2012年)和5年随访检查(2012 - 2017年)的一部分,通过非接触眼压计测量眼压。在两个时间点记录全身用药情况。进行多变量回归分析以分析关联。此外,我们计算了选择性β受体阻滞剂剂量变化与5年内眼压变化的剂量反应关系。
分析人群包括9633名参与者的19161只眼睛。新开始使用选择性β受体阻滞剂的参与者眼压变化较低(-0.31 mmHg,P < 0.001),而停止使用选择性β受体阻滞剂的参与者眼压升高(+0.28 mmHg,P = 0.02)。眼压变化与他汀类药物和钙通道阻滞剂(CCB)之间的关联可归因于联合用药。选择性β受体阻滞剂摄入量变化与眼压变化之间存在剂量反应关系(-0.16 mmHg/100 mg,P = 0.02)。
在人群层面,全身使用选择性β受体阻滞剂与眼压变化相关,而与其他全身用药对眼压变化的关联可通过联合用药或血压变化来解释。接受眼压监测和管理的患者应常规询问全身用药的变化情况。